“ Biopharmaceutical
Company Based on
VLP Platform Technology ”

The researchers in POSVAX have established the technology to select the perfect form of virus-like particles based on protein structure analysis and immunological researches for the last 15 years. We already have secured a higher level of manufacturing technology for highly pure VLPs through applying genetic recombination technology and enhanced culture-purification technology. With these technologies, based on VLP platform, we aim to develop near-impossible and highly valuable prophylactic vaccines for cervical cancer, head-neck cancer, RSV, and Alzheimer's disease. Furthermore, using the accumulated technology, we will also develop new anticancer drugs with high efficacy.

The researchers in POSVAX have established the technology to select the perfect form of virus-like particles based on protein structure analysis and immunological researches for the last 15 years. We already have secured a higher level of manufacturing technology for highly pure VLPs through applying genetic recombination technology and enhanced culture-purification technology.